

Table S4. Associations of changes in cytokine, autoantibody and IC levels between baseline and month 6 with treatment outcome.

Sustained outcomes	SRI-4		cSLEDAI-2K=0		cSLEDAI-2K=0 & prednisone eq. ≤7.5 mg/day		LLDAS	
Variables	+	-	+	-	+	-	+	-
	P value		P value		P value		P value	
Cytokines								
IFN-α2	1.000		0.397		0.356		0.716	
IL-6	0.216		0.172		0.147		0.149	
IL-10	0.957		0.358		0.269		0.541	
IL-17A	0.894		0.622		0.638		0.517	
Autoantibodies								
Anti-dsDNA	0.362		0.612		0.876		0.198	
Anti-ribosomal P	0.669		0.717		0.950		0.064	
Anti-histone	0.206		0.852		0.876		-0.8 (-2.6; -0.1)	-6.2 (-19.6; -0.6)
							0.031	
Anti-Sm	0.391		0.192		0.160		-0.1 (-3.5; 0.9)	-1.0 (-25.8; -0.2)
							0.013	
Anti-U1RNP	0.453		-0.5 (-6.6; -0.1)	-5.1 (-31.4; -0.2)	0.072		0.341	
			0.040					
Anti-Sm-U1RNP	0.061		0.069		0.124		-0.2 (-5.3; 0.1)	-3.3 (-15.4; -0.4)
							0.038	
Anti-Ro52/SSA	0.138		0.649		0.678		0.594	
Anti-Ro60/SSA	0.105		0.066		-0.5 (-2.8; 1.9)	-2.7 (-7.0; -0.2)	-0.2 (-3.3; 2.1)	-2.8 (-7.1; -1.0)
					0.031		0.011	
Anti-La/SSB	0.238		0.357		0.454		0.0 (-1.2; 0.3)	-0.9 (-3.7; -0.1)
							0.028	
Circulating IC	0.138		0.381		0.599		0.437	

P values derived from comparisons of changes in cytokine (pg/mL), autoantibody (AU or IU/mL) and IC (μ g Eq/mL) levels between baseline and month 6 ($\Delta_{(\text{month 6} - \text{baseline})}$) between patients who attained and patients who did not attain sustained SRI-4, cSLEDAI-2K = 0, cSLEDAI-2K = 0 & prednisone equivalent dose ≤ 7.5 mg/day, and LLDAS, using Mann-Whitney *U* test. Distributions of variables are presented as medians (25th percentile; 75th percentile) in cases of significant P values. Light grey shadows indicate statistically significant associations between Δ s and the respective outcome.

cSLEDAI-2K: clinical Systemic Lupus Erythematosus Disease Activity Index 2000; dsDNA: double stranded DNA; IFN: interferon; IC: immune complex; IL: interleukin; LLDAS: Lupus Low Disease Activity State; PCNA: proliferating cell nuclear antigen; Sm: Smith.